[HER2-positive breast cancer: standard and double targeted therapy].
Vopr Onkol
; 59(3): 341-6, 2013.
Article
en Ru
| MEDLINE
| ID: mdl-23909035
ABSTRACT
Neoadjuvant systemic therapy is frequently used option for the systemic treatment for breast cancer. Inclusion in the regimen of targeted drugs as trastuzumab (Herceptin) and pertuzumab significantly improves outcomes in HER2-positive breast cancer patients. A certain part of HER2-positive patients can be cured by using only targeted drugs without chemotherapy.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias de la Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Biomarcadores de Tumor
/
Receptor ErbB-2
/
Terapia Neoadyuvante
/
Terapia Molecular Dirigida
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Middle aged
Idioma:
Ru
Revista:
Vopr Onkol
Año:
2013
Tipo del documento:
Article